Treatment of Relapsed/Refractory AML—Novel Treatment Options Including Immunotherapy

Journal: American Journal of Hematology
Credit: 1.0 AMA PRA Category 1 Credit^TM
Release Date: February 18, 2025

Abstract

Acute myeloid leukemia is a molecularly heterogenous disease caused by the rapid expansion and impaired differentiation of malignant myeloid progenitors. Overall, outcomes remain poor, and more than half of patients develop relapsed or refractory disease after front-line therapy. Allogeneic hematopoietic stem cell transplant (HCT) remains the best chance for cure for eligible patients, and the development of novel therapies including BCL2, FLT3, IDH1/2 and menin inhibitors, which are efficacious yet generally more tolerable, have enabled better bridging to prompt HCT. Despite the early success of targeted therapies, more generalized and efficacious therapeutic approaches remain in need, and numerous targeted immunotherapeutic agents (including CAR-T, bispecific and trispecific antibody therapies) are currently under investigation.

Activity Disclosures

The publication of this supplement has been funded by Abbvie Inc.

A.S. serves as a member on the Amgen Speaker Bureau and is a consultant for Debiopharm. A.T.F. provides clinical trial support for Abbvie, Servier, and BMS, and is a consultant for the following companies: BMS, Servier, Astellas, Abbvie, PureTech, Forma, Daiichi Sankyo, Pfizer, Rigel, Autolus, Amgen, Takeda, Orum, Menarini, Remix, Ipsen, Gilead, Genentech, AstraZeneca, Syndax, Schrodinger, Prelude. The other authors declare no conflicts of interest.

This activity underwent peer review in line with standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Accreditation

John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 1 hour. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, a score of 70% or better is needed to pass the post test.